Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Takumi Kawaguchi, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):177-180. Published online August 26, 2021

DOI: https://doi.org/10.3350/cmh.2021.0246

View: 4480 Download: 175 Web of Science: 2 Crossref: 2

Wataru Ando, Hiroaki Yokomori, Nobuhiro Tsutsui, Eigoro Yamanouchi, Yutaka Suzuki, Masaya Oda, Yutaka Inagaki, Katsuya Otori, Isao Okazaki

Clin Mol Hepatol. 2018;24(1):61-76. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0030

View: 9259 Download: 170 Web of Science: 25 Crossref: 28

Michael G. Tovey

Clin Mol Hepatol. 2002;8(2):125-131. Published online January 1, 1970

View: 4022 Download: 27

Jong Myung Lee , Young Oh Kweon , Nung Soo Kim

Clin Mol Hepatol. 1997;3(2):170-178. Published online January 1, 1970

View: 8923 Download: 12

1 |

Viewed By 5606	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4826	MAFLD: How is it different from NAFLD?
Viewed By 4566	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3728	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3715	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search